ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,942.47
1.26%
US Tech 100
20,762.73
1.73%
다우존스 지수
42,732.13
0.80%
Bitcoin
97,960.27
-0.25%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NYSE
  6. Organon and Co (OGN)

  7. Organon and Co (OGN) 뉴스

OGN

Organon (OGN)

Organon and Co
일자:
정렬 기준:
 검색 관련기사 보기:NYSE:OGN
일자시간출처헤드라인심볼기업
2024/12/2320:01Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
2024/12/1921:30Business WireOrganon To Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNYSE:OGNOrganon and Co
2024/12/1621:30Business WireFDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and OlderNYSE:OGNOrganon and Co
2024/12/0706:15Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
2024/11/0521:40Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
2024/11/0521:29Business WireUpdate on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and OlderNYSE:OGNOrganon and Co
2024/11/0121:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:OGNOrganon and Co
2024/10/3121:40Business Wire米国FDAが、PROLIA/XGEVA（デノスマブ）のバイオシミラー候補HLX14の生物学的製剤承認申請（BLA）を受理NYSE:OGNOrganon and Co
2024/10/3121:39Business WireUS-amerikanische FDA akzeptiert BLA für HLX14 – den Biosimilar-Kandidat zu PROLIA/XGEVA (Denosumab)NYSE:OGNOrganon and Co
2024/10/3121:39Business Wire美國FDA接受PROLIA/XGEVA（地諾單抗）生物學名藥候選藥物HLX14的生物製品授權申請(BLA)NYSE:OGNOrganon and Co
2024/10/3121:00Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
2024/10/3120:30Business WireOrganon Reports Results for the Third Quarter Ended September 30, 2024NYSE:OGNOrganon and Co
2024/10/3113:02Business WireLa FDA des États-Unis accepte la demande de licence de produits biologiques (BLA) pour HLX14, le candidat biosimilaire de PROLIA/XGEVA (denosumab)NYSE:OGNOrganon and Co
2024/10/3019:00Business WireUS FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)NYSE:OGNOrganon and Co
2024/10/3001:22Business WireOrganon vollzieht Übernahme von Dermavant einschließlich der innovativen dermatologischen Therapie VTAMA® (Tapinarof) Creme, 1 %NYSE:OGNOrganon and Co
2024/10/3001:22Business Wireオルガノン、ダーマバントの買収を完了し、画期的な皮膚科治療薬VTAMA®（タピナロフ）クリーム1％を取得NYSE:OGNOrganon and Co
2024/10/3001:22Business WireOrganon conclut l'acquisition de Dermavant, qui propose notamment un traitement dermatologique innovant : la crème VTAMA® (tapinarof) 1 %NYSE:OGNOrganon and Co
2024/10/2822:25Business WireOrganon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%NYSE:OGNOrganon and Co
2024/10/2822:25GlobeNewswire Inc.Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%NYSE:OGNOrganon and Co
2024/10/0920:30Business WireOrganon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024NYSE:OGNOrganon and Co
2024/10/0821:01PR Newswire (Canada)Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established BrandsNYSE:OGNOrganon and Co
2024/10/0821:01PR Newswire (Canada)Organon Canada promeut Geneviève Gauthier au poste de directrice exécutive, Affaires corporatives et Engagement communautaire, et nomme Jeffrey Malawski comme directeur exécutif, Santé des femmes et marques établiesNYSE:OGNOrganon and Co
2024/10/0104:26Business Wireパージェタ（Perjeta®）（ペルツズマブ）バイオシミラー候補HLX11の第3相比較臨床試験で主要評価項目を達成NYSE:OGNOrganon and Co
2024/10/0101:17Business WirePrimärer Endpunkt in Phase-3-Vergleichsstudie zu Perjeta® (Pertuzumab) Biosimilar-Kandidat HLX11 erreichtNYSE:OGNOrganon and Co
2024/10/0100:59Business WireCritères principal atteint dans une étude clinique comparative de phase 3 sur le candidat biosimilaire HLX11 du Perjeta® (pertuzumab)NYSE:OGNOrganon and Co
2024/09/3019:00Business WirePrimary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11NYSE:OGNOrganon and Co
2024/09/2622:50PR Newswire (Canada)Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in CanadaNYSE:OGNOrganon and Co
2024/09/2622:49PR Newswire (Canada)Organon Canada et l'Alberta Women's Health Foundation s'unissent pour accroître la sensibilisation et prôner l'accès universel à la contraception au CanadaNYSE:OGNOrganon and Co
2024/09/2405:21Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
2024/09/2003:30Business WireオルガノンがDermavantを買収し、画期的な皮膚科治療薬VTAMA®（タピナロフ）クリーム1%を取得NYSE:OGNOrganon and Co
 검색 관련기사 보기:NYSE:OGN

최근 히스토리

NYSE
XOM
Exxon Mobil
SPI
SP500
S&P 500
CCOM
US30
US 30
FX
USDJPY
US Dollar vs Yen
NASDAQ
AAPL
Apple
CCOM
SILVER
SILVER
COIN
ADAUSD
Cardano
NYSE
VZ
Verizon Communications
PM
XAUUSD
Gold vs US Dollar
COIN
SOLUSD
Solana
FX
USDEUR
US Dollar vs Euro
USOTC
BASFY
BASF (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
NKE
Nike
NYSE
MRK
Merck
NYSE
CVX
Chevron
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유